Live feed08:30:00·9mPRReleasevia QuantisnowActinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate CancerByQuantisnow·Wall Street's wire, on your screen.ATNM· Actinium Pharmaceuticals Inc. (Delaware)Health Care
